文献速递头颈与中枢神经肿瘤

纳武利尤单抗治疗高危口腔白斑:一项非随机对照试验

Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项非随机、开放标签的2期临床试验在单个学术医疗中心纳入33例高危增殖性疣状白斑患者,给予4剂纳武利尤单抗480 mg静脉注射、每28天一次。复合评分缓解率为36%(95%CI 20.4%-54.8%),9例(27%)在试验期间发生口腔鳞状细胞癌,2年无癌生存率为73%(95%CI 53%-86%)。

要点

  • 33例高危增殖性疣状白斑患者接受4剂纳武利尤单抗480 mg静脉注射,每28天一次。
  • 12例(36%)达复合评分缓解,其中3例(9%)为主要缓解。
  • 9例(27%)试验期间发生口腔鳞状细胞癌,2年无癌生存率73%。

核心结论

  • 该免疫检查点治疗癌前病变的非随机临床试验达到预设缓解终点,提示纳武利尤单抗在高危增殖性疣状白斑中可能具有临床活性。
  • 研究发现了免疫基因组学关联,可为这一医疗需求未满足且难以研究的癌前疾病的未来试验提供信息。

研究设计与样本

  • 非随机、开放标签的2期临床试验,2019年1月至2021年12月在单个学术医疗中心开展,中位随访21.1个月(范围5.4-43.6个月)。
  • 纳入基于人群样本的增殖性疣状白斑患者,病灶为多灶性、连续性或单个病灶≥4 cm且伴任何程度异型增生,共33例;中位年龄63岁(范围32-80岁),18例(55%)为女性,8例(24%)有既往切除的早期口腔鳞状细胞癌。
  • 治疗前活检1-3个部位,随后接受4剂纳武利尤单抗480 mg静脉注射、每28天一次,之后再次活检并在每次访视时行口内拍照。

主要发现

  • 12例(36%)(95%CI 20.4%-54.8%)达复合评分缓解,其中3例(9%)为主要缓解。
  • 4例为疾病进展(复合评分增加>10%或发生癌症);9例(27%)在试验期间发生口腔鳞状细胞癌,2年无癌生存率为73%(95%CI 53%-86%)。
  • 2例(6%)因毒性作用停药;7例(21%)发生3至4级免疫相关不良事件。
  • PD-L1联合阳性评分与缓解或无癌生存无关。
  • 20例接受全外显子测序的患者中,纳武利尤单抗治疗后进展为口腔鳞状细胞癌的全部6例在治疗前活检均显示9p21.3体细胞拷贝数缺失,而未发生口腔鳞状细胞癌的14例中仅4例(29%)有9p21.3缺失。

关键数值与推荐

  • 主要终点为治疗前后复合评分(大小和异型增生程度)变化:主要缓解为评分下降>80%,部分缓解为下降40%-80%。
  • 疾病进展定义为复合评分增加>10%或发生癌症。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Proliferative verrucous leukoplakia (PVL) is an aggressive oral precancerous disease characterized by a high risk of transformation to invasive oral squamous cell carcinoma (OSCC), and no therapies have been shown to affect its natural history. A recent study of the PVL immune landscape revealed a cytotoxic T-cell-rich microenvironment, providing strong rationale to investigate immune checkpoint therapy. OBJECTIVE: To determine the safety and clinical activity of anti-programmed cell death 1 protein (PD-1) therapy to treat high-risk PVL. DESIGN, SETTING, AND PARTICIPANTS: This nonrandomized, open-label, phase 2 clinical trial was conducted from January 2019 to December 2021 at a single academic medical center; median (range) follow-up was 21.1 (5.4-43.6) months. Participants were a population-based sample of patients with PVL (multifocal, contiguous, or a single lesion ≥4 cm with any degree of dysplasia). INTERVENTION: Patients underwent pretreatment biopsy (1-3 sites) and then received 4 doses of nivolumab (480 mg intravenously) every 28 days, followed by rebiopsy and intraoral photographs at each visit. MAIN OUTCOMES AND MEASURES: The primary end point was the change in composite score (size and degree of dysplasia) from before to after treatment (major response [MR]: >80% decrease in score; partial response: 40%-80% decrease). Secondary analyses included immune-related adverse events, cancer-free survival (CFS), PD-1 ligand 1 (PD-L1) expression, 9p21.3 deletion, and other exploratory immunologic and genomic associations of response. RESULTS: A total of 33 patients were enrolled (median [range] age, 63 [32-80] years; 18 [55%] were female), including 8 (24%) with previously resected early-stage OSCC. Twelve patients (36%) (95% CI, 20.4%-54.8%) had a response by composite score (3 MRs [9%]), 4 had progressive disease (>10% composite score increase, or cancer). Nine patients (27%) developed OSCC during the trial, with a 2-year CFS of 73% (95% CI, 53%-86%). Two patients (6%) discontinued because of toxic effects; 7 (21%) experienced grade 3 to 4 immune-related adverse events. PD-L1 combined positive scores were not associated with response or CFS. Of 20 whole-exome sequenced patients, all 6 patients who had progression to OSCC after nivolumab treatment exhibited 9p21.3 somatic copy-number loss on pretreatment biopsy, while only 4 of the 14 patients (29%) who did not develop OSCC had 9p21.3 loss. CONCLUSIONS AND RELEVANCE: This immune checkpoint therapy precancer nonrandomized clinical trial met its prespecified response end point, suggesting potential clinical activity for nivolumab in high-risk PVL. Findings identified immunogenomic associations to inform future trials in this precancerous disease with unmet medical need that has been difficult to study. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03692325.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hanna GJ, Villa A, Nandi SP, et al. Nivolumab for Patients With High-Risk Oral Leukoplakia: A Nonrandomized Controlled Trial. JAMA Oncol. 2024. PMID: 37971722. doi:10.1001/jamaoncol.2023.4853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。